Boston, MA — February 3, 2026 — Leads & Copy — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has unveiled QIAsprint Connect at SLAS 2026 in Boston, marking its entry into high-throughput benchtop automation for sample processing in research labs.
The compact system can handle up to 192 samples per run. It has customizable workflows, an intuitive user interface, and a modular kit design. Its sustainability-focused consumables reduce plastic use and packaging waste.
QIAGEN also presented QIAsymphony Connect, a platform for high-yield DNA and RNA extraction in clinical laboratories, and QIAmini, a compact automation system for low-throughput labs.
According to Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN, high-throughput labs face pressure to process more samples without sacrificing flexibility, reliability or sustainability. He said QIAsprint Connect is designed to help labs meet those demands and reflects QIAGEN’s strategy to expand automation across all throughput needs.
Sood noted a key advantage is the series of QIAsprint consumables kits designed to deliver performance across multiple applications while championing eco-friendly packaging and resource efficiency. He added that the launch complements the launches of QIAsymphony Connect and QIAmini to strengthen its offering in this starting point in lab workflows.
QIAsprint Connect combines high-throughput capacity, workflow flexibility and sustainability-focused design to support demanding research applications:
- High-throughput efficiency: Processes up to 192 samples per run with minimal manual intervention.
- Flexible workflow design: Supports QIAGEN-tested and fully customizable protocols via touch-based interface and modular chemistry.
- Sustainability-focused consumables: Reduces plastic use by up to 50% and also cuts packaging volume by 40%.
- Compact benchtop footprint: Provides high-throughput capability in a space-saving format for existing lab environments.
- Connectivity and compliance readiness: Supports modern data integrity and cybersecurity requirements, including 21 CFR Part 11 readiness.
QIAGEN will unveil QIAsprint Connect live at SLAS 2026 in Boston on February 9 at 2:30 p.m. EST.
The QIAGEN booth will also feature two additional automated extraction systems planned for launch this year:
- QIAsymphony Connect: The next generation of QIAGEN’s automated sample preparation platform, designed for high-yield DNA and RNA isolation in clinical applications with complete sample tracking and standardized workflows.
- QIAmini: A compact, benchtop automation solution designed to provide walkaway sample preparation for lower-throughput laboratories seeking an accessible and user-friendly entry into automation.
To learn more about QIAGEN’s activities at SLAS 2026, visit www.qiagen.com/SLAS2026.
QIAGEN N.V. is a Netherlands-based holding company and a global provider of Sample to Insight solutions. It serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare).
As of December 31, 2025, QIAGEN employed approximately 5,700 people across more than 35 locations.
Source: QIAGEN N.V.
